GNNSF (Genscript Biotech) EV-to-EBITDA : -34.93 (As of May. 28, 2025)

View and export this data going back to 2017. Start your Free Trial

What is Genscript Biotech EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Genscript Biotech's enterprise value is $2,972.2 Mil. Genscript Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was $-85.1 Mil. Therefore, Genscript Biotech's EV-to-EBITDA for today is -34.93.

The historical rank and industry rank for Genscript Biotech's EV-to-EBITDA or its related term are showing as below:

GNNSF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -44.96 Med: 3.63 Max: 147.4
Current: -33.9

During the past 11 years, the highest EV-to-EBITDA of Genscript Biotech was 147.40. The lowest was -44.96. And the median was 3.63.

GNNSF's EV-to-EBITDA is ranked worse than
100% of 501 companies
in the Biotechnology industry
Industry Median: 8.16 vs GNNSF: -33.90

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-28), Genscript Biotech's stock price is $1.355. Genscript Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $1.359. Therefore, Genscript Biotech's PE Ratio (TTM) for today is 1.00.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).

Genscript Biotech EV-to-EBITDA Historical Data

The historical data trend for Genscript Biotech's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech EV-to-EBITDA Chart

Genscript Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EV-to-EBITDA

Get a 7-Day Free Trial

-8.75

-17.91

-16.88

18.24

-26.69

Genscript Biotech Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EV-to-EBITDA	Get a 7-Day Free Trial															-16.88	-	18.24	-	-26.69

Competitive Comparison of Genscript Biotech's EV-to-EBITDA

For the Biotechnology subindustry, Genscript Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genscript Biotech's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genscript Biotech's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Genscript Biotech's EV-to-EBITDA falls into.

Save Embed

;

Save Embed

;

Genscript Biotech EV-to-EBITDA Calculation

Genscript Biotech's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	2972.229	/	-85.095
	=	-34.93

Genscript Biotech's current Enterprise Value is $2,972.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genscript Biotech's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was $-85.1 Mil.

Genscript Biotech (OTCPK:GNNSF) EV-to-EBITDA Explanation

Genscript Biotech's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	1.355	/	1.359
	=	1.00

Genscript Biotech's share price for today is $1.355.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genscript Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $1.359.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Genscript Biotech EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Genscript Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (OTCPK:GNNSF) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

01548:Hong Kong G51:Germany

Address

No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100

Website

https://www.genscript.com

Genscript Biotech Corp is a China-based provider of life science research services and products. The firm is known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. The company's business segments include Life-science services and products, Biologics development services, Industrial synthetic biology products, and the Operation unit. The company generates the majority of its revenue from the life-science services and products unit, which provides comprehensive research services and products, which are widely used and are fundamental to life-science research and application. Geographically, the company generates the majority of its revenue from the United States of America, followed by Mainland China.